Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: Results from the 24-month follow-up of the BELA trial

Tim H. Brümmendorf, Jorge E. Cortes, Cármino Antonio de Souza, Francois Guilhot, Ladan Duvillié, Dmitri Pavlov, Karïn Gogat, Athena M. Countouriotis, Carlo Gambacorti-Passerini

Research output: Contribution to journal › Article › peer-review

159 Scopus citations

Fingerprint

Dive into the research topics of 'Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: Results from the 24-month follow-up of the BELA trial'. Together they form a unique fingerprint.

Medicine & Life Sciences